Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Zydus Cadila gets...

    Zydus Cadila gets USFDA nod to market 2 generic drugs

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-05-01T20:05:18+05:30  |  Updated On 13 Aug 2021 3:50 PM IST

    New Delhi: Drug firm Zydus Cadila Tuesday said it has received the final nod from the USFDA to market generic Bosentan tablets and Trientine Hydrochloride capsules in the US.


    The company has received final approval from the US health regulator to market Bosentan tablets USP in strengths of 62.5 mg and 125 mg and Trientine Hydrochloride capsules USP in the strength of 250 mg, Zydus Cadila said in a statement.


    Read Also: Zydus Cadila gets final USFDA nod for Leflunomide tablets to treat arthritis


    "Both products will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad," it added.


    While Bosentan tablets are a generic version of Tracleer tablets, Trientine Hydrochloride capsules are a generic version of Syprine capsules, Zydus Cadila said.


    Bosentan is used to treat high blood pressure in the lungs, it added.


    Read Also: Zydus Cadila gets USFDA nod for Phentermine Hydrochloride orally disintegrating tablets


    Trientine works by removing copper from the blood. It is used to treat Wilson's disease, a genetic metabolic defect that causes excess copper to build up in the body. It is recommended to patients who cannot take penicillamine, Zydus Cadila said.


    The group now has 265 approvals and has so far filed over 350 abbreviated new drug applications (ANDAs) since the commencement of its filing process, it added.


    Read Also: Zydus Cadila gets final USFDA nod to generic version of Diamox for injection


    Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 322 per scrip on BSE, down 1.80 per cent from the previous close.

    abbreviated new drug applicationsANDAsblood pressureBosentan tabletsCadila HealthcareDrug firm Zydus Cadilageneric Bosentan tabletsgeneric drugsgeneric versionNew DelhipenicillamineShares of Cadila HealthcareSyprine capsulesTracleer tabletsTrientine Hydrochloride capsulesUSUS healthUSFDAZydus Cadila
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok